

## PATENT

Docket No. GC527- US  
SN 09/060,872

☐ Urgent  
☐ Confidential  
☐ Action Required  
☐ Reply Requested  
☐ For Your Info.

**FAX COVER SHEET**

TO: Art Unit 1644

LOCATION: USPTO

Fax No.: (703) 872-9306 (Before Final Facsimile No.)

FROM: Carol See for Kamrin T. MacKnight

LOCATION: GENENCOR INTERNATIONAL, INC.  
Legal Department  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-7549  
Fax: 650-845-6504

FAX RECEIVED

SEP 27 2002  
GROUP 1600

OFFICIAL

DATE: September 26, 2002

NUMBER OF PAGES TO FOLLOW: 10 SENT BY: cas

Re: Serial No. 09/060,872, Attorney Docket No. GC527- US

Attachments: Transmittal (1 page) in duplicate, Amendment and Response to  
Office Action (8 pages).

The original of this facsimile will be sent to you via:

☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent

☒ Please initial acknowledgment of receipt by return facsimile \_\_\_\_\_

NOTE: The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone( 650/846-7517) and return the original transmission to us by mail.

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Facsimile No. 703-872-9306, (Before Final Facsimile No.) Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: September 26, 2002

By Carol A. See  
Carol A. See

**PATENT**  
**Docket No. GC527-US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application:	)	
	)	
Estell et al.	)	Group Art Unit: 1644
	)	
Serial No.: 09/060,872	)	Examiner: Saunders, David A.
	)	
Filed: April 15, 1998	)	
	)	
For: Mutant Proteins Having Lower Allergenic	)	
Response in Humans and Methods for	)	
Constructing, Identifying and Producing Such	)	
Proteins	)	

**TRANSMITTAL LETTER**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 09, 2002, enclosed please find the following document: Amendment and Response to Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527-US). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: September 26, 2002

Kamrin T. MacKnight  
Kamrin T. MacKnight  
Registration No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-5838  
Fax: 650-845-6504

GC527-US-T-OFFACT

Received from < 650 845 6504 > at 9/26/02 1:41:49 PM [Eastern Daylight Time]

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.5(d) addressed to Art Unit 1644, Facsimile No. 703-872-9306, (Before Final Facsimile No.) Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: September 26, 2002

By Carol A. See

Carol A. See

**PATENT**  
**Docket No. GC527-US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application:

Estell et al.

Serial No.: 09/060,872

Filed: April 15, 1998

For: Mutant Proteins Having Lower Allergenic  
Response in Humans and Methods for  
Constructing, Identifying and Producing Such  
Proteins

Group Art Unit: 1644

Examiner: Saunders, David A.

**AMENDMENT AND RESPONSE TO OFFICE ACTION**  
**MAILED SEPTEMBER 9, 2002**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 9, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following remarks. Applicants are submitting this Response prior to the thirty (30) day/one (1) month deadline provided in the Office Action. Thus, Applicants believe that no Extension of Time Fees are required.

A clean version of the rewritten, added, and/or cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) is included beginning on page 2 of this communication. A marked-up version of rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear

GC527-US-amendment

Received from < 650 845 6504 > at 9/26/02 1:41:49 PM [Eastern Daylight Time]